Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Diluted Average) (2021 - 2025)

Sunshine Biopharma's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $2.7 million for Q1 2025.

  • For Q1 2025, Shares Outstanding (Diluted Average) rose 321.53% year-over-year to $2.7 million; the TTM value through Mar 2025 reached $2.7 million, up 321.53%, while the annual FY2024 figure was $701749.0, 5371.73% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $2.7 million in Q1 2025 per SBFM's latest filing, up from $701749.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $25.7 million in Q3 2023 to a low of $12825.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $8.9 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 99.92% in 2023, then skyrocketed 5371.73% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then plummeted by 99.92% to $12825.0 in 2023, then surged by 5371.73% to $701749.0 in 2024, then soared by 285.22% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Shares Outstanding (Diluted Average) are $2.7 million (Q1 2025), $701749.0 (Q4 2024), and $641310.0 (Q1 2024).